Gesynta Pharma
CompanySwedenFounded 2017
Gesynta Pharma develops one asset, in phase 2 (vipoglanstat in endometriosis). Mostly small molecule acting on PTGES; based in Sweden, founded in 2017.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $32.9M
- 1
- Trial
- 0
- Signals
Pipeline
1Inhibits microsomal prostaglandin E synthase-1, reducing production of pro-inflammatory prostaglandin E2.
Phase 2, Small molecule, PTGES, endometriosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Funding rounds and grants2
- Signals1
- Similar companies6